S-P's 4th-qtr 2007 results hit by Organon buy

18 February 2008

US drug major Schering-Plough's fourth-quarter 2007 results were hit by costs related to last year's acquisition of Organon BioSciences from Netherlands-based Akzo Nobel for 11.0 billion euros ($16.3 billion; Marketletters passim).

On a generally-accepted accounting principles basis, the Kenilworth, New Jersey-based firm saw a net loss of $3.4 billion, or $2.08 per common share. Earnings per share would have been $0.27, excluding purchase accounting adjustments and items related to the Organon merger, which closed on November 19, 2007, as well as other items. Net turnover totaled $3.7 billion versus $2.7 billion, beating the Reuters Estimates prediction of $3.53 billion in sales and EPS of $0.24.

4th-qtr sales of Vytorin/Zetia jump 34%

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight